title: Poly(lactic acid) microspheres for the sustained release of antiischemic agents.
abstract: We report a preliminary study evaluating the encapsulation modalities in microparticles of the antiischemic drug N(6)-cyclopentyladenosine (CPA). The effects of release systems have been evaluated on the stability in human whole blood of CPA and its affinity toward human adenosine A(1) receptors. The microspheres were prepared by an emulsion-solvent evaporation method (different CPA amounts and two stirring rates were employed) using poly(lactic acid). Free and encapsulated CPA was incubated in human blood and the drug stability was analyzed. The affinity of CPA to human A(1) receptor was also obtained in the presence and in the absence of unloaded microspheres. The microspheres obtained using 1200 rpm showed a broad size distribution and a mean diameter value of 21+/-9 microm. Using 1700 rpm the mean diameter decreased to 5+/-2 microm and a more homogeneous size distribution was obtained. The CPA release changed with the particle size and the different amounts of drug employed during the preparation of the microspheres. The degradation in human whole blood of CPA encapsulated in the microspheres was negligible, with respect to that of free CPA. Affinity values of CPA obtained in the absence and in the presence of unloaded microspheres were the same.
authors.affiliation: Dipartimento di Scienze Farmaceutiche, Ferrara University, via Fossato di Mortara 19, 44100, Ferrara, Italy. dla@dns.unife.it
authors.forename: A
authors.initials: A
authors.lastname: Dalpiaz
authors.forename: A
authors.initials: A
authors.lastname: Scatturin
authors.forename: B
authors.initials: B
authors.lastname: Pavan
authors.forename: C
authors.initials: C
authors.lastname: Biondi
authors.forename: M A
authors.initials: MA
authors.lastname: Vandelli
authors.forename: F
authors.initials: F
authors.lastname: Forni
mesh_terms: D000241:Adenosine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000378:metabolism; D000818:Animals; D016466:CHO Cells; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D006224:Cricetinae; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D006801:Humans; D066298:In Vitro Techniques; D019344:Lactic Acid; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D011091:Polyesters; D011108:Polymers; D018047:Receptors, Purinergic P1 / Q000378:metabolism
chemical_list: D002317:Cardiovascular Agents; D003692:Delayed-Action Preparations; D011091:Polyesters; D011108:Polymers; D018047:Receptors, Purinergic P1; D019344:Lactic Acid; C048599:N(6)-cyclopentyladenosine; C033616:poly(lactide); D000241:Adenosine